Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Burton RC, Bell RJ, Thiagarajah G, Stevenson C (2011) Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Res Treat
2.
Kopans DB (2005) Bias in the Medical Journals: a commentary. AJR Am J Roentgenol 185:176–182PubMed
3.
Kopans DB (2005) Informed decision making: age of 50 is arbitrary and has no demonstrated influence on breast cancer screening in women. AJR Am J Roentgenol 185:177–182PubMed
4.
Kopans DB, Moore RH, McCarthy KA, Hall DA, Hulka C, Whitman GJ, Slanetz PJ, Halpern EF (1998) Biasing the interpretation of mammography screening data by age grouping: nothing changes abruptly at age 50. Breast J 4:139–145CrossRef
Metadata
Title
Not so fast: the use of incomplete data to devalue the role of mammography screening
Author
Daniel B. Kopans
Publication date
01-05-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-1966-z

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue

Preclinical study

Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis

Epidemiology

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice

Erratum

Erratum to: Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment

Clinical trial

Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?

Clinical trial

Prospective study of breast tomosynthesis as a triage to assessment in screening

Preclinical Study

Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits